(Total Views: 490)
Posted On: 03/10/2021 8:53:40 AM
Post# of 145873
What went wrong? We had 20.5% mortality for leronlimab. Based on EINDs I figured we'd get 17% to 20% so not much off there. Where things go awry is in the 21.6% percent in the placebo. A bit of that would be accountable from improved SOC, quite a bit of that could be accountable from the skew in 65+ year old patients.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)